Considering that silibinin has extremely high antioxidant and anti-tumor properties, it has drawn our attention to its potential use in the treatment of GBM.BNIP3, a member of the Bcl-2 family of pro-apoptotic proteins and a receptor for mitophagy, exhibits context-dependent roles in cancer(Gorbunova et al., 2020; Gorbunova et al., 2020; Vara-Perez et al., 2021).It targets mitochondria and could induce mitochondrial damage and nuclear translocation of AIF6 (Su et al., 2016). The gene discussed is BCL2; the disease is glioblastoma.